Noticias y eventos de YARW (YARW)YARWYARW

Yarrow Initiates Phase 2a/2b Trial for YB-101

"The second quarter was highly productive for Yarrow and included the initiation of our Phase 2a/2b clinical trial of YB-101, a potential first-in-class anti-TSHR antibody that represents a highly differentiated approach to treating both Graves' disease and thyroid eye disease. These two diseases converge on the TSHR, a single receptor that no approved therapy targets directly, giving Yarrow the unique opportunity to treat both conditions with a single molecule," said Rebecca V. Frey, PharmD, President and Chief Executive Officer of Yarrow. "With the merger with VYNE Therapeutics now complete and cash runway expected to fund operations into 2028, we're well-positioned to advance YB-101 in GD, where dosing is underway and Phase 2a data are expected in the second half of 2027. Additionally, GenSci continues its Phase 1 MAD study in TED in China, which we expect to inform our global TED development plans."